Abstract
The pharmacokinetics and bioavailability of nitrazepam following intravenous, oral (tablet), and rectal (solution) administration were studied in seven healthy, young male volunteers. Nitrazepam plasma concentrations were determined by electron-capture GLC; pharmacokinetic evaluations were made by compartmental analysis (NONLIN) and compared with the results obtained by a less stringent modelling of the data. The plasma concentration-time profile was similar for all three routes of administration. Mean kinetic parameters as obtained by compartmental analysis of i.v. nitrazepam were: distribution half-life 17 min; volume of distribution after equilibrium 2.14 liters/kg; total plasma clearance 61.6 ml/min; elimination half-life 29.0 h. The mean protein unbound fraction of nitrazepam in plasma was 12.3% and the clearance of the unbound fraction was 506 ml/min. Absorption of oral nitrazepam started after the elapse of a lag time (mean value 12 min) and occurred as an apparent first-order process in all but one subject, with a mean absorption half-life of 16 min. Distribution and elimination half-lives were comparable with those following i.v. administration. Following rectal administration of the nitrazepam solution, rapid first-order absorption occurred with a mean lag time of 4 min and a mean absorption half-life of 9 min. Peak times (median 18 min) were significantly shorter than following oral administration (median 38 min), but there was little difference in peak concentrations. The distribution half-life was similar to i.v. and oral administration, but the elimination half-lives were longer with a mean value of 33.1 h. Following i.v. administration a good agreement was found between the results obtained by compartmental analysis using NONLIN and those obtained by a less stringent modelling of the data. Following oral and rectal administration, a good agreement between the two procedures was found for the elimination half-life; estimation of bioavailability, however, was higher by compartmental analysis. The mean bioavailability data showed that absorption is complete when nitrazepam is given orally and almost 20% lower when it is given rectally, but considerable interindividual differences were observed.
Similar content being viewed by others
References
D. D. Breimer, H. Bracht, and A. G. de Boer. Plasma level profile of nitrazepam (Mogadon) following oral administration.Br. J. Clin. Pharmacol. 4:709–711 (1977).
L. Kangas, H. Allonen, R. Lammintausta, M. Salonen, and A. Pekkarinen. Pharmacokinetics of nitrazepam in saliva and serum after a single oral dose.Acta Pharmacol. Toxicol. 45:20–24 (1979).
L. Kangas, J. Kanto, V. Lehtinen, and J. Salminen. Long-term nitrazepam treatment in psychiatric out-patients with insomnia.Psychopharmacology 63:63–66 (1979).
L. Kangas, E. Iisalo, J. Kanto, V. Lehtinen, S. Pynnönen, I. Ruikka, J. Salminen, M. Sillanpää, and E. Syvälahti. Human pharmacokinetics of nitrazepam: effect of age and disease.Eur. J. Clin. Pharmacol. 15:163–170 (1979).
J. Rieder. Plasma levels and derived pharmacokinetic characteristics of unchanged nitrazepam in man.Arzneim.-Forch. 23:212–218 (1973).
A. Meberg, A. Langslet, J. E. Bredesen, and P. K. M. Lunde. Plasma concentration of diazepam and N-desmethyldiazepam in children after a single rectal or intramuscular dose of diazepam.Eur. J. Clin. Pharmacol. 14:273–276 (1978).
I. Magnussen, H. R. W. Oxlund, K. E. Alsbirk, and E. Arnold. Absorption of diazepam in man following rectal and parenteral administration.Acta Pharmacol. Toxicol. 45:87–90 (1979).
A. G. de Boer, J. Röst-Kaiser, H. Bracht, and D. D. Breimer. Assay of underivatized nitrazepam and clonazepam in plasma by capillary gas chromatography applied to pharmacokinetic and bioavailability studies in humans.J. Chromatogr. 145:105–114 (1978).
C. M. Metzler, G. L. Elfring, and A. J. McEwen. A package of computer programs for pharmacokinetic modelling.Biometrics 30:562 (1974).
J. G. Wagner.Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Hamilton Ill., 1975.
C. A. Naranjo, E. M. Sellers, and V. Khouw. Fatty acids modulation of meal-induced variations in diazepam free fraction.Br. J. Clin. Pharmacol. 10:308–310 (1980).
E. M. Sellers, C. A. Naranjo, J. G. Abel, K. M. Piafsky, and P. Sandor. Fatty acids as a source of variation in drug binding.Acta Pharmaceut. Suecica 17:88 (1980).
K. Iga, S. Hirai, and T. Yashika. Assessment of local and systemic availability of tribenoside after rectal administration in rats.Int. J. Pharmacol. 6:43–54 (1980).
E. Iisalo, L. Kangas, and I. Ruikka. Pharmacokinetics of nitrazepam in young volunteers and aged patients.Br. J. Clin. Pharmacol. 4:646P (1977).
R. Jochemsen, M. van der Graaff, J. K. Boeijinga, and D. D. Breimer. Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.Br. J. Clin. Pharmacol.,13:319–324 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jochemsen, R., Hogendoorn, J.J.H., Dingemanse, J. et al. Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans. Journal of Pharmacokinetics and Biopharmaceutics 10, 231–245 (1982). https://doi.org/10.1007/BF01059259
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01059259